Skip Nav Destination
Issues
15 March 2010
-
Cover Image
Cover Image
Human pancreatic cancer–associated fibroblasts (CAFs) overexpress the Hedgehog receptor SMO. Here, immunohistochemical labeling highlights overexpression of Smo protein in a human primary pancreatic adenocarcinoma. Strong Smo expression is detected in stromal fibroblasts adjacent to pancreatic cancer cells. For details, see the article by Walter and colleagues on page 1781 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
Molecular Pathways
CCR Special Focus
Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents
Janet E. Dancey; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Kevin K. Dobbin; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Susan Groshen; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; J. Milburn Jessup; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Andrew H. Hruszkewycz; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Maria Koehler; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Ralph Parchment; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Mark J. Ratain; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Lalitha K. Shankar; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Walter M. Stadler; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Lawrence D. True; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Amy Gravell; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee; Michael R. Grever; On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee
The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee
Lesley Seymour; S. Percy Ivy; Daniel Sargent; David Spriggs; Laurence Baker; Larry Rubinstein; Mark J. Ratain; Michael Le Blanc; David Stewart; John Crowley; Susan Groshen; Jeffrey S. Humphrey; Pamela West; Donald Berry
Review
Human Cancer Biology
Cancer Therapy: Preclinical
PEA-15 Inhibits Tumorigenesis in an MDA-MB-468 Triple-Negative Breast Cancer Xenograft Model through Increased Cytoplasmic Localization of Activated Extracellular Signal-Regulated Kinase
Chandra Bartholomeusz; Ana M. Gonzalez-Angulo; Anna Kazansky; Savitri Krishnamurthy; Ping Liu; Linda X. H. Yuan; Fumiyuki Yamasaki; Shuying Liu; Naoki Hayashi; Dongwei Zhang; Francisco J. Esteva; Gabriel N. Hortobagyi; Naoto T. Ueno
Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer
Srinivas Nagaraj; Je-In Youn; Hannah Weber; Cristina Iclozan; Lily Lu; Matthew J. Cotter; Colin Meyer; Carlos R. Becerra; Mayer Fishman; Scott Antonia; Michael B. Sporn; Karen T. Liby; Bhupendra Rawal; Ji-Hyun Lee; Dmitry I. Gabrilovich
Targeted Inhibition of Inducible Nitric Oxide Synthase Inhibits Growth of Human Melanoma In vivo and Synergizes with Chemotherapy
Andrew G. Sikora; Alexander Gelbard; Michael A. Davies; Daisuke Sano; Suhendan Ekmekcioglu; John Kwon; Yared Hailemichael; Padmini Jayaraman; Jeffrey N. Myers; Elizabeth A. Grimm; Willem W. Overwijk
Imaging, Diagnosis, Prognosis
Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome
Nicholas J. Dickens; Brian A. Walker; Paola E. Leone; David C. Johnson; José L. Brito; Athanasia Zeisig; Matthew W. Jenner; Kevin D. Boyd; David Gonzalez; Walter M. Gregory; Fiona M. Ross; Faith E. Davies; Gareth J. Morgan
Value of Magnetic Resonance Spectroscopy Imaging and Dynamic Contrast-Enhanced Imaging for Detecting Prostate Cancer Foci in Men With Prior Negative Biopsy
Alessandro Sciarra; Valeria Panebianco; Mauro Ciccariello; Stefano Salciccia; Susanna Cattarino; Danilo Lisi; Alessandro Gentilucci; Andrea Alfarone; Silvia Bernardo; Roberto Passariello; Vincenzo Gentile
Cancer Therapy: Clinical
Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial
Alan S. Wayne; Robert J. Kreitman; Harry W. Findley; Glen Lew; Cynthia Delbrook; Seth M. Steinberg; Maryalice Stetler-Stevenson; David J. FitzGerald; Ira Pastan
Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer
Massimo Cristofanilli; Vicente Valero; Aroop Mangalik; Melanie Royce; Ian Rabinowitz; Francis P. Arena; Joan F. Kroener; Elizabeth Curcio; Claire Watkins; Sarah Bacus; Elsa M. Cora; Elizabeth Anderson; Patrick J. Magill
A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies
Bart Kuenen; Petronella O. Witteveen; Rita Ruijter; Giuseppe Giaccone; Aruna Dontabhaktuni; Floyd Fox; Terry Katz; Hagop Youssoufian; Junming Zhu; Eric K. Rowinsky; Emile E. Voest
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Patricia M. LoRusso; Smitha S. Krishnamurthi; John J. Rinehart; Lisle M. Nabell; Lisa Malburg; Paul B. Chapman; Samuel E. DePrimo; Steven Bentivegna; Keith D. Wilner; Weiwei Tan; Alejandro D. Ricart
Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer
Helen J. Ross; George R. Blumenschein,, Jr.; Joseph Aisner; Nevena Damjanov; Afshin Dowlati; Jennifer Garst; James R. Rigas; Michael Smylie; Habib Hassani; Kimberly E. Allen; Lance Leopold; Tal Z. Zaks; Frances A. Shepherd
Susceptibility and Prevention
Letters to the Editor
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.